NCT01908595已完成3 期
An Open-label, Multi-center, Long-term Study to Evaluate the Safety and Efficacy of M518101 in Subjects With Plaque Psoriasis
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 480
- 试验地点
- 31
- 主要终点
- Time course change of Investigator Global Assessment
研究概览
简要总结
This study is to evaluate the efficacy and safety for long term use of M518101 in subjects with plaque psoriasis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Who are able and willing to give signed informed consent
- •Who are male or females aged 18 years or older with plaque psoriasis confirmed by the Investigator.
- •Who have up to 20% of body surface area (BSA) afflicted with plaques
- •Who are neither pregnant nor breast-feeding, nor plan to become pregnant during the study.
排除标准
- •Who have a history of allergy to vitamin D3 derivative preparations or a history of relevant drug hypersensitivity.
- •Who are pregnant or lactating.
- •Who have any renal or hepatic insufficiency, or clinically significant cardiac, renal or hepatic disease.
- •Who are not deemed eligible as determined by medical history, physical examination or clinical laboratory safety tests.
- •Who have clinically relevant history or presence of any disease or surgical history other than psoriasis which is likely to affect the conduct of the study.
- •Whose serum calcium levels exceed the upper limit of reference range
- •Who have used any investigational medicinal product and/or participated in any clinical study within 60 days of treatment.
- •Who have been treated with systemic therapy within 30days of treatment.
- •Who have treated with biologics within 5 half-lives of the biologics before the day of treatment
- •Who have been treated with topical therapy within 14days before the day of treatment.
研究组 & 干预措施
M518101
Experimental
Proper quantity twice daily
干预措施: M518101 (Drug)
结局指标
主要结局
Time course change of Investigator Global Assessment
时间窗: 4 weeks interval
次要结局
未报告次要终点
研究者
研究点 (31)
Loading locations...
相似试验
未知
3 期
M518101 phase III 52-Week long term study in plaque psoriasis and palmoplantar keratoderma patientsPlaque psoriasis and palmoplantar keratodermaJPRN-jRCT2080222895Maruho Co.,Ltd.
已完成
不适用
Long-term Safety and Efficacy Follow-up Study of PNEUMOSTEM® in Patients Who Completed PNEUMOSTEM® Phase-I StudyRespiratory Tract InfectionsPremature Birth of NewbornBronchopulmonary DysplasiaNCT02023788Medipost Co Ltd.8
已完成
1 期
A Study to Evaluate Long-term Safety and Clinical Activity of Givosiran (ALN-AS1) in Patient With Acute Intermittent Porphyria (AIP)Acute Intermittent PorphyriaNCT02949830Alnylam Pharmaceuticals16
已完成
4 期
A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based TherapyRelapsed and/or Refractory Multiple MyelomaNCT03416374Takeda45
Unknown
不适用
Long-term Safety and Efficacy of FURESTEM-CD Inj. in Patients With Moderately Active Crohn's Disease(CD)Crohn's DiseaseNCT02926300Kang Stem Biotech Co., Ltd.24